Annual report pursuant to Section 13 and 15(d)

Stockholders' equity - Stock Option Activity (Details)

v3.24.1
Stockholders' equity - Stock Option Activity (Details) - USD ($)
12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Exercise Price Per Share [Abstract]    
Outstanding, Exercise Price Lower Range Limit (usd per share) $ 0.71 $ 0.71
Outstanding, Exercise Price Upper Range Limit (usd per share) 10.33  
Granted, Exercise Price Lower Range Limit (usd per share) 0.88  
Granted, Exercise Price Upper Range Limit (usd per share) 1.10 $ 10.33
Canceled and Forfeited, Exercise Price Lower Range Limit (usd per share) 0.71  
Canceled and Forfeited, Exercise Price Upper Range Limit (usd per share) $ 4.50  
Tecogen    
Stock Options Outstanding [Roll Forward]    
Beginning (shares) 3,204,297  
Granted (shares) 575,000 761,650
Canceled and forfeited (shares) (141,175)  
Ending (shares) 3,638,122 3,204,297
Exercisable (shares) 1,953,197  
Vested and expected to vest (shares) 3,385,353  
Weighted Average Exercise Price [Roll Forward]    
Beginning (usd per share) $ 1.61  
Granted (usd per share) 0.93  
Canceled and forfeited (usd per share) 1.81  
Ending (usd per share) 1.49 $ 1.61
Vested and expected to vest (usd per share) 1.53  
Exercisable (usd per share) $ 1.95  
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]    
Outstanding, Aggregate Intrinsic Value $ 127,811 $ 882,074
Exercisable, Aggregate Intrinsic Value 77,961  
Vested and expected to vest, Aggregate Intrinsic Value $ 120,333  
Exercise Price Per Share [Abstract]    
Granted, Exercise Price Lower Range Limit (usd per share)   $ 1.10
Stock Options | Tecogen    
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Additional Disclosures [Abstract]    
Outstanding, Weighted Average Remaining Life 6 years 8 months 12 days 7 years 3 months 18 days